Omabit Raises $2M Seed Round Led by Bright Ventures

We've raised a $2 million seed round led by Bright Ventures.

Drug developers generate large amounts of evidence across their studies, but it rarely gets used together. Omabit combines a team's own genomic and clinical data with published research. Clinical development, biomarker and translational teams can then dig into questions like who responded to a treatment and why, and use that to plan the next trial.

The funding goes into building the platform and growing our science and engineering team.

Read the full announcement on Business Wire, or the coverage in GenomeWeb.

Working on a question your data should be able to answer? We'd love to talk.